Cordex Signs European Development Partnership for ATPotent(TM) Sperm Mot...(n in the male reproductive tract and is ...),Health

Date:6/22/2009

n in the male reproductive tract and is a mandatory co-factor of fertilization in the female reproductive tract. Cordex's sponsored studies have shown that ATP treatment can improve the motility and fertilization capacity of malfunctioning sperm obtained from infertile males due to asthenozoospermia as well as thawed sperm that had been cryopreserved.

About Cordex Pharma, Inc.

Cordex is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development. ATPace(TM) is expected to enter a Phase 2b/3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Cordex's CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment of heart failure. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary diseases. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations,
'/>"/>

SOURCE Cordex Pharma, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
2. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
3. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
4. VivoMetrics(R) Introduces Next Generation LifeShirt Prototype, a Smart Garment That Delivers Real-time Vital Signs Remotely to Healthcare Providers
5. Moffitt Cancer Center Signs Licensing Agreement with Frantz BioMarkers, LLC
6. Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs
7. Optigenex Inc. Signs New License and Distribution Agreement With Itochu Corporation of Japan
8. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
9. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
10. Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
11. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years